Key facts
- Complement 1’s last known valuation is $60.0M (May 2025).
- It has raised $16.0M; the latest was Seed Round ($16.0M) in May 2025.
- Notable investors include Blume Venture Advisors, Owl Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Complement 1
- ·The full record, as it builds
Funding rounds
No funding rounds for Complement 1 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Complement 1
Operator of a healthcare platform intended to improve cancer-related health outcomes. The company's software helps daily life intervention zero wait time, customized services for cancer treatment, type and stage, enabling clients to get relevant information regarding cancer exercise and cancer nutrition.
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2024
- Employees
- 20
- Website
- complement1.com/
- Ownership
- Privately Held (backing)
Complement 1 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Complement 1 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Complement 1 in its N-PORT filings yet. We sweep new filings monthly.